Download PDF
Thromb Haemost 2000; 83(05): 637-638
DOI: 10.1055/s-0037-1613882
Commentary
Schattauer GmbH

Recombinant Factor VIIa Is a Pan-hemostatic Agent?

Louis M. Aledort
1   From the Mount Sinai Medical Center, the Mount Sinai Hospital, New York, NY, USA
› Author AffiliationsThis study was supported in part by Health Services Administration Grant MCB-360001; Health and Human Services Grant HS-30567; the Regional Comprehensive Hemophilia Diagnostic and Treatment Center; the Margie Boas Fund; the International Hemophilia Training Center of the World Federation of Hemophilia; the Polly Annenberg Levee Hematology Center, Department of Medicine, Mount Sinai School of Medicine of the City University of New York; and grant 5MO1RR0071 for the Mount Sinai General Clinical Research Center from the National Center for Research Resources, National Institutes of Health.
Further Information

Publication History

Publication Date:
08 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost 1999; 82: 531-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Monroe DM, Hoffman M, Oliver JA, Robert HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
    CrossrefPubMedGoogle Scholar
  • 3 Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104: 22-6.
    CrossrefPubMedGoogle Scholar
  • 5 Hedner U. Recombinant activated factor VII as a universal hemostatic agent. Blood Coag Fibrinol 1998; (Suppl. 01) 147-52.
    PubMedGoogle Scholar
  • 6 d’Oiron R, Ménart C, Trzeciak MC, Nurden P, Fressinaud E, Dreyfus M, Laurian Y, Négrier C. Recombinant factor VIIa in Glanzmann’s thrombasthenia: A potential therapeutic place. Thromb Haemost 2000; 83: 644-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Turacek PL, Richter G, Muchitson EM, Pichler L, Schwarz HP, Morrissey J. Thrombogenicity of recombinant factor VIIa and recombinant soluble tissue factor in an in vivo rabbit model. Thromb Haemost 1997; Suppl. June: 222: 903.
    PubMedGoogle Scholar
  • 8 Clinical experience with NovoSeven. Summary of efficacy and safety. August 1996.
    PubMedGoogle Scholar
  • 9 European public assessment report on NovoSeven. 1996; 28: 10.
    PubMedGoogle Scholar
  • 10 Peerlinck KK, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in a patient with haemophilia A and inhibitor. Thromb Haemost 1999; 82: 1775-6.
    Article in Thieme ConnectPubMedGoogle Scholar